Metabolically healthy and unhealthy obesity: differential effects on myocardial function according to metabolic syndrome, rather than obesity. by Dobson, R et al.
Accepted Article Preview: Published ahead of advance online publication
Metabolically healthy and unhealthy obesity: differential effects
on myocardial function according to metabolic syndrome, rather
than obesity
R Dobson, M I Burgess, V S Sprung, A Irwin, M Hamer, J
Jones, C Daousi, V Adams, G J Kemp, F Shojaee-Moradie, M
Umpleby, D J Cuthbertson
Cite this article as: R Dobson, M I Burgess, V S Sprung, A Irwin, M Hamer, J
Jones, C Daousi, V Adams, G J Kemp, F Shojaee-Moradie, M Umpleby, D J
Cuthbertson, Metabolically healthy and unhealthy obesity: differential effects on
myocardial function according to metabolic syndrome, rather than obesity,
International Journal of Obesity accepted article preview 14 August 2015; doi:
10.1038/ijo.2015.151.
This is a PDF ﬁle of an unedited peer-reviewed manuscript that has been accepted
for publication. NPG are providing this early version of the manuscript as a service
to our customers. The manuscript will undergo copyediting, typesetting and a proof
review before it is published in its ﬁnal form. Please note that during the production
process errors may be discovered which could affect the content, and all legal
disclaimers apply.
Received 7 May 2015; revised 9 July 2015; accepted 3 August 2015; Accepted
article preview online 14 August 2015
©    2015 Macmillan Publishers Limited. All rights reserved.
 1 
Metabolically healthy and unhealthy obesity: differential effects on myocardial function 
according to metabolic syndrome, rather than obesity. 
Running title: Metabolically healthy obesity and preserved cardiac function 
Rebecca Dobson
1
, Malcolm I Burgess
2
, Victoria S Sprung
1
, Andrew Irwin
1
, Mark Hamer
3
, 
Julia Jones
2
, Christina Daousi
1
, Valerie Adams
4
, Graham J Kemp
4,5
, Fariba Shojaee-
Moradie
6
, Margot Umpleby
6
, Daniel J Cuthbertson
1 
1
Department of Obesity and Endocrinology, Institute of Ageing and Chronic Disease, 
University of Liverpool, L69 3GA 
2 
Department of Cardiology, University Hospital Aintree, Lower Lane, Liverpool, L9 7AL 
3
National Centre Sport & Exercise Medicine, Loughborough University 
4
Magnetic Resonance and Image Analysis Research Centre, University of Liverpool, 
Pembroke Place, Liverpool, L69 3GE 
5
Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, 
University of Liverpool, L69 3GA 
6
Diabetes and Metabolic Medicine, Faculty of Health and Medical Sciences, University of 
Surrey, Guildford 
 
Corresponding author and address for reprints: Dr Rebecca Dobson 
Clinical Sciences Centre, Aintree University Hospital, Lower Lane, Liverpool, L9 7AL 
E-mail: Rebecca.dobson@liverpool.ac.uk, Tel 0151 529 5917, Fax 0151 529 5888 
Key words: metabolically healthy obesity, metabolic syndrome, liver fat, visceral fat, 
myocardial function. 
Funding:  Funding was provided by the European Foundation for the Study of Diabetes, 
Rheindorfer Weg 3, 40591 Dusseldorf, Germany 
Conflicts of interest: The authors declare no conflict of interest 
 
©    2015 Macmillan Publishers Limited. All rights reserved.
 2 
Abstract  
Background The term “metabolically healthy obesity (MHO)” is distinguished using body 
mass index (BMI), yet BMI is a poor index of adiposity. Some epidemiological data suggest 
that MHO carries a lower risk of cardiovascular disease (CVD) or mortality than being 
normal weight yet metabolically unhealthy.   
Objectives We aimed to undertake a detailed phenotyping of individuals with MHO by using 
imaging techniques to examine ectopic fat (visceral and liver fat deposition) and myocardial 
function. We hypothesised that metabolically unhealthy individuals (irrespective of BMI) 
would have adverse levels of ectopic fat and myocardial dysfunction compared to MHO 
individuals.  
Subjects Individuals were categorised as non-obese or obese (BMI ≥ 30 kg.m-2) and as 
metabolically healthy or unhealthy according to the presence or absence of metabolic 
syndrome.  
Methods 67 individuals (mean±SD: age 49±11 years) underwent measurement of i) visceral, 
subcutaneous and liver fat using magnetic resonance imaging and proton magnetic resonance 
spectroscopy, ii) components of metabolic syndrome, iii) cardiorespiratory fitness, and iv) 
indices of systolic and diastolic function using tissue Doppler echocardiography.  
Results Cardiorespiratory fitness was similar between all groups; abdominal and visceral fat 
was highest in the obese groups.  Compared with age- and BMI-matched metabolically 
healthy counterparts, the unhealthy (lean or obese) individuals had higher liver fat and 
decreased early diastolic strain rate, early diastolic tissue velocity and systolic strain 
indicative of subclinical systolic and diastolic dysfunction.  The magnitude of dysfunction 
correlated with the number of components of metabolic syndrome but not with BMI or with 
the degree of ectopic (visceral or liver) fat deposition.  
©    2015 Macmillan Publishers Limited. All rights reserved.
 3 
Conclusions Myocardial dysfunction appears to be related to poor metabolic health rather 
than simply BMI or fat mass. These data may partly explain the epidemiological evidence on 
CVD risk relating to the different obesity phenotypes. 
 
Introduction 
Obesity has been considered to confer an increased risk of cardiovascular disease (CVD) and 
mortality 
1, 2
. However, there is increasing recognition of a subgroup of obese patients with 
the mechanical complications of obesity but without the associated metabolic complications: 
„metabolically healthy obesity‟ (MHO) 3. 
There is conflicting data in the literature regarding metabolic risk and obesity, and whether 
metabolic risk is determined more by the relative distribution than the absolute volume of fat.  
Metabolically healthy individuals have increased subcutaneous fat relative to visceral fat and 
lower cellular fat in liver and skeletal muscle in comparison to metabolically unhealthy 
individuals 
4
.  They are also more insulin-sensitive and have a better inflammatory status 
5, 6
. 
Several studies have demonstrated that the quantity of liver fat is more closely linked to the 
metabolic complications of obesity than that of visceral fat 
7-9
.  However, there is conflicting 
evidence that suggests excess visceral fat and insulin resistance, but not general adiposity are 
associated with incident pre-diabetes and type 2 diabetes in obese individuals 
10
.  A recent 
study of almost 30,000 individuals demonstrated that metabolically unhealthy obese 
individuals have a greater risk of developing diabetes than the metabolically healthy obese
11
. 
Although this area remains contentious, a number of epidemiological studies have 
demonstrated that MHO individuals are also at a lower risk of CVD, and have reduced 
morbidity and mortality compared to the metabolically unhealthy obese, suggesting that 
cardio-metabolic risk factors are more strongly associated with adverse cardiovascular 
outcomes than obesity 
12-16
. However, not all data suggests a protective effect. A recent study 
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suggested that MHO confers increased risk of heart failure, but not acute myocardial 
infarction 
17
. Similarly, the risk of developing CVD in the San Antonio Heart Study was 
found to be increased in MHO 
18
. A recent systematic review and meta-analysis found that, 
after 10 years of follow-up, MHO is associated with an increased risk of total mortality and 
cardiovascular events 
19
.  
Several cross-sectional studies have tried to better understand the association between 
metabolic health and CVD by examining the impact of components of metabolic syndrome 
on cardiac function. Developments in echocardiographic techniques have improved the 
detection of relatively subtle myocardial disease 
20
.  Strain and strain rate are sensitive 
measures of change of myocardial shape (i.e. deformation).  Strain indicates the amount of 
myocardial deformation (negative strain means shortening and positive strain, elongation); 
strain rate, is a measure of the rate of myocardial deformation.  Measurement of strain and 
strain rate detect pre-clinical myocardial abnormalities, which can help predict risk of 
cardiovascular events and mortality 
21
. In patients with metabolic syndrome, subclinical left 
ventricular (LV) dysfunction has been detected (lower early diastolic and systolic tissue 
velocities accompanied by reduced strain and strain rates) compared to matched controls, 
worse in those with a greater number of components of the metabolic syndrome 
22, 23
.  
Considering the influence of liver fat on metabolic health and the association of non-
alcoholic fatty liver disease (NAFLD) with features of the metabolic syndrome 
24
, others have 
looked at NAFLD patients and demonstrated subclinical myocardial systolic and diastolic 
dysfunction in the presence or absence of type 2 diabetes (T2DM) 
25, 26
. 
The main aim of this cross-sectional study was to determine whether metabolically unhealthy 
individuals irrespective of their BMI or normal weight, overweight or obese category, have 
evidence of increased ectopic fat (with higher visceral and liver fat deposition), combined 
with impaired myocardial function, compared with age- and BMI-matched metabolically 
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healthy individuals. Furthermore we hypothesised that MHO individuals would have little 
evidence of ectopic fat and preserved myocardial function similar to normal weight 
(metabolically healthy) individuals despite their overall higher fat mass. This would provide a 
mechanistic context for the epidemiological data around CVD risk and the different obesity 
phenotypes. We employed a combination of whole body magnetic resonance imaging (MRI) 
to look at ectopic fat and sensitive echocardiographic measures to measure myocardial 
function. 
 
Subjects and Methods 
Subjects Patients with hyperlipidemia and suspected NAFLD were prospectively recruited 
from specialist lipid and hepatology outpatient clinics at University Hospital Aintree, 
Liverpool. To recruit metabolically healthy lean and obese individuals we relied on local 
advertisements.  As the association of BMI and metabolic health with cardiac outcomes was a 
novel investigation, the effect size of interest was unknown. No formal sample size was 
calculated and recruitment of patients was based on availability with the hope that the 
estimates obtained will inform future studies.  The study conformed to the Declaration of 
Helskinki and Liverpool Research Ethics Committee approved the study (Ethics Reference 
09/H1005/7). All participants gave written informed consent.   
 
Individuals aged >21 years with a body mass index (BMI) < 40 kg/m
2
 who were able to walk 
on a treadmill and undergo MRI scanning were recruited. Those with a history of CVD 
(including atrial fibrillation, ischemic heart disease, heart failure or valvulopathy), type 1 or 
type 2 diabetes mellitus or chronic liver disease (other than NAFLD) were excluded. 
Individuals with a BMI > 40kg/m
2 
were excluded due to the technical challenges of 
performing high quality echocardiographic studies on those with morbid obesity. All females 
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and males consumed <14 and <21 units of alcohol per week respectively. We recorded the 
following medications: diuretics, statins, ezetimibe, ACE inhibitors, calcium channel 
antagonists and beta-blockers in all participants.  
 
Anthropometry Age, gender, smoking status, past medical history, drug history and family 
history of CVD were established using a series of questionnaires.  Smoking status was 
defined as never, former or current smoker.  Physical activity levels were determined using 
the long format International Physical Activity Questionnaire 
27
.  Alcohol intake was 
determined using the Alcohol Use Disorders Identification Test questionnaire 
28
. Blood 
pressure was measured on at least two separate occasions, with the patient sitting for at least 
10 minutes. Body mass was measured after an overnight fast, without shoes, using a Tanita 
bioimpedance analyser, which also determined fat-free mass and fat percentage (Tanita 
BC420, Dolby Medical, Stirling, UK).  Height was measured with a stadiometer to the 
nearest 0.5 cm (Seca, Birmingham, UK).  BMI was calculated as weight in kilograms divided 
by height in metres, squared.  Waist circumference was measured at the midpoint between the 
anterior superior iliac spine and the lower edge of the ribcage.  The same individual 
undertook all anthropometric measurements.   
 
Determinations of metabolic syndrome (MS) Participants were classified as obese (BMI ≥ 30 
kg/m
2
) or non-obese (BMI < 30kg/m
2
), and with or without the metabolic syndrome (MS+ vs 
MS-). MS was defined by the Adult Treatment Panel III 
29
 as three or more of the following: 
waist circumference >102 cm (male) or >88 cm (female), triglycerides >1.7 mmol/L (or 
treatment for hyperlipidemia), HDL cholesterol <1mmol/L (male) or <1.3 mmol/L (female), 
systolic blood pressure >130mmHg, diastolic blood pressure >85 mmHg (or treatment for 
©    2015 Macmillan Publishers Limited. All rights reserved.
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hypertension) and fasting glucose > 6.1 mmol/L. Ten year risk of first atherosclerotic 
cardiovascular event was calculated using the Pooled Cohort Risk Assessment Equation
30
. 
 
Magnetic resonance imaging and proton magnetic resonance spectroscopy Participants 
underwent magnetic resonance (MR) scanning using a 1.5T Siemens Symphony scanner 
(Siemens Medical Solutions, Erlangen, Germany) at the University of Liverpool Magnetic 
Resonance and Image Analysis Research Centre. A single experienced radiographer 
performed all of the scans.   
 
Abdominal axial T1-weighted fast spin echo scans (axial scans, 10 mm slice thickness 
followed by a 10 mm gap using the integrated body coil) were used to calculate abdominal 
visceral and subcutaneous adipose tissue
31
. A blinded researcher performed all analyses of 
visceral and subcutaneous fat centrally.  
 
Liver lipid was measured non-invasively using proton magnetic resonance spectroscopy (
1
H-
MRS) as previously described 
31-33
. NAFLD was defined as intrahepatocellular lipid content 
(IHCL) > 5.5% measured by 
1
H-MRS. Three voxels of interest were identified in the liver 
avoiding ducts and vasculature and the mean value taken after data were processed 
independently. 
1
H MR spectra from liver was quantified using the AMARES algorithm in the 
software package jMRUI-3.0. Intrahepatocellular lipid is expressed as percentage of CH2 
lipid signal amplitude relative to water signal amplitude after correcting for T1 and T2. Fat 
quantification by 
1
H-MRS has been validated against gold standard biochemical 
measurements 
34
. 
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Biochemical markers and assays Venous blood samples were obtained from participants after 
an overnight fast (minimum 8 hours).  Serum lipid profiles, liver function and glucose were 
measured using standard proprietary agents using the Olympus AU2700 analyser (Beckman 
Coulter (UK) Ltd). Plasma insulin and adiponectin were measured by radioimmunoassay 
using commercially available kits (Millipore Corporation, Billerica, MA; intra-assay CV 6% 
and 5% respectively). All patients with NAFLD underwent a routine liver screen (antinuclear, 
parietal cell, mitochondrial, smooth muscle, reticulin, liver kidney microsomal type 1 and 
anti-centromere antibodies, ceruloplasmin and ferritin levels and hepatitis serology). 
 
Cardiopulmonary exercise testing Incremental cardiopulmonary exercise testing was 
performed on a treadmill (Model 77OCE, RAM Medisoft Group) using a modified Bruce 
protocol. Breath-by-breath expiratory gases and ventilation analysis were performed (Love 
Medical Cardiopulmonary Diagnostics, Cheshire). Following a 3-minute warm-up at 2.8 
km/h with no gradient, the initial workload was set at 2.8 km/h with a 5% gradient. 
Thereafter, stepwise increments were made in gradient and/or speed every 3 minutes as per 
the Modified Bruce Protocol.  Peak patient effort was defined by any of i) a respiratory 
exchange ratio > 1.1, ii) heart rate > 90% of predicted maximum, iii) a plateau in VO2, or iv) 
patient exhaustion 
35
.  Continuous electrocardiographic monitoring was used and all tests 
were physician-supervised. 
 
Trans-thoracic echocardiography image acquisition and interpretation All echocardiograms 
were performed using a GE Vivid 7 or E9 machine with a 2.5 MHz phased array transducer 
and the patient in the left lateral position on a reclining couch. A combination of 2D, M-
mode, pulsed wave and continuous wave Doppler and tissue Doppler was used. Conventional 
©    2015 Macmillan Publishers Limited. All rights reserved.
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echocardiographic views were obtained (parasternal long axis, parasternal short axis, apical 4 
chamber, apical long axis, apical 2 chamber and subcostal). 
 
LV diameter and wall thicknesses were measured in the parasternal long axis view using 2D 
or M-mode measurements. LV mass was calculated using Devereux‟s formula and was 
indexed to body surface area 
36
. Modified Simpson‟s biplane method was used to determine 
LV ejection fraction. Mitral inflow velocities and deceleration times were measured using 
pulsed wave Doppler in the apical 4 chamber view. Isovolumetric relaxation time was 
calculated using continuous wave Doppler, with the cursor midway between left ventricular 
outflow and mitral inflow. For tissue Doppler imaging, colour tissue Doppler loops were 
recorded using a frame rate >100 frames/sec. Myocardial longitudinal function was assessed 
from three consecutive cycles of tissue Doppler imaging in the apical 4 chamber, apical 2 
chamber and apical long axis views. 
 
Echocardiographic data was analysed using Echopac V9.01, GE, Horten, Norway. Peak 
systolic and early and late diastolic myocardial tissue velocities were obtained from the basal 
segment of all 6 LV walls. Myocardial deformation curves were obtained from the basal 
segment of all 6 LV walls. Wall motion was manually tracked throughout the cardiac cycle to 
maintain continuity of the sampling area. Data were excluded if a smooth curve was 
unobtainable, or if the angle between the ventricular wall and the scan line was >20
0
. From 
these curves, peak systolic strain, systolic and early and late diastolic strain rates were 
obtained. Using data from each of the 3 cardiac cycles, the values from each wall were 
averaged to give a mean value. 
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Statistical analysis Continuous variables are presented as mean±standard deviation or median 
(interquartile range) if non-normally distributed; categorical variables are presented as 
frequencies and percentages. Univariate statistical comparisons of patient demographics 
between groups were conducted; for continuous variables using a one-way analysis of 
variance or a Kruskal-Wallis test when non-normal; for categorical variables, using a Chi-
Squared test or a Fisher‟s Exact test when cell frequencies were insufficient. P-values were 
corrected for multiple comparisons using Sime‟s procedure and declared as significant if a P-
value <0.017 was achieved.  
 
A multiple linear regression model was fitted to investigate the association of BMI and 
metabolic syndrome on cardiac function. A two-way interaction of the main effects was 
investigated and retained if a p-value < 0.1 was obtained. Sensitivity analysis was conducted, 
adjusting the final model for age and gender. To explore the association between cardiac 
function and the number of metabolic syndrome components a univariate regression model 
was fitted. To investigate the relative strength of each metabolic syndrome component on 
cardiac function, all variables were standardised. A multivariable linear regression model was 
fitted including the metabolic syndrome components as main effects and then adjusted for 
age and gender. No interactions were investigated and results are expressed as the SD change 
in cardiac function associated with a one SD increment in the independent variable.  
 
The association of liver fat with cardiac function was analysed using Spearman‟s correlation 
coefficient.  
 
Model fit was assessed using QQ plots and standardised residuals against predicted means 
plots. Results were declared as significant if P<0.05. All statistical analyses were conducted 
©    2015 Macmillan Publishers Limited. All rights reserved.
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using Stata IC 13 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, 
TX: StataCorp LP). 
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Results  1 
Clinical characteristics (Table 1): 67 participants were recruited, of whom 2 were excluded 2 
(1 with left bundle branch block on electrocardiography, 1 unable to tolerate MR scanning).  3 
22 participants had ≥3 components of the metabolic syndrome: 21 (96%) had the waist 4 
circumference component, 18 (82%) the triglyceride component, 16 (73%) the blood pressure 5 
component, 12 (55%) the HDL cholesterol component and 8 (36%) the glucose component.  6 
Tables 1 & 2 and Figure 1 show mean results in the 4 groups formed by the two 7 
classifications, obese vs. non-obese and with (MS+) vs. without (MS-) metabolic syndrome. 8 
There were no significant differences between the four groups in terms of age, gender, 9 
systolic blood pressure, smoking status or cardiorespiratory fitness (Table 1). 10 year 10 
cardiovascular risk was highest in the MS+ groups.  11 
 12 
Higher proportions of those in the MS+ groups were taking medication for hypertension or 13 
hyperlipidaemia, reflecting the higher prevalence of these conditions. In non-obese MS- 1 14 
patient was taking an ACE inhibitor, 2 calcium channel antagonists and 6 statins; in non-15 
obese MS+ 2 were taking calcium channel antagonists, 3 statins, 1 diuretics and 1 ezetimibe; 16 
in obese MS- 1 patient was taking a statin; in obese MS+, 5 were taking ACE inhibitors, 1 17 
calcium channel antagonists, 2 beta-blockers, 4 statins and 1 ezetimibe.  18 
 19 
Metabolic and biochemical data (Table 1): There were significant differences in fasting 20 
triglyceride, HDL cholesterol and glucose concentrations between the four groups. HbA1C 21 
was <4.5 in all individuals.  Insulin concentrations were significantly different between 22 
groups (P=0.002) with higher levels observed in the obese groups. There were no significant 23 
differences in adiponectin concentrations between the groups.  The liver screen was negative 24 
for all patients included in the study.   25 
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Body composition data (Table 1): As expected, there was a significant difference in BMI 26 
across the four groups (P<0.001). The obese groups had greater subcutaneous adipose tissue 27 
and visceral adipose tissue than the non-obese groups, although there was no significant 28 
difference in their relative proportion (VAT:SAT ratio). The intrahepatocellular lipid content 29 
was up to four times higher in the metabolically unhealthy patients in comparison to the 30 
metabolically healthy, however the difference across groups did not reach statistical 31 
significance  (P=0.055).   32 
 33 
Echocardiographic data: In terms of left ventricular (LV) morphology, there were no 34 
significant differences across the groups in LV mass, posterior wall thickness , LV mass 35 
indexed to body surface area, LV septal wall thickness or LV internal diastolic diameter 36 
(Table 2).   37 
 38 
In terms of LV systolic function, LV ejection fraction, systolic tissue velocity (S‟) and peak 39 
systolic longitudinal strain rate did not differ significantly across the groups, however, there 40 
was a significant difference in peak systolic (longitudinal) strain (P=0.001) (Table 2 and 41 
Figure 1A). Linear regression showed that patients with MS had significantly lower peak 42 
systolic strain than those without (= -2.45: 95% CI -3.74, -1.15; P<0.001), with a 43 
progressive reduction in peak systolic strain as the number of MS components increased 44 
(Figure 2A, Table 4A). Of the metabolic syndrome components, triglycerides were 45 
significantly associated with peak systolic strain (for a one SD increase: -0.29: 95% CI -0.53, 46 
-0.04; P=0.021) (Table 4B).  47 
 48 
A higher BMI was associated with a lower peak systolic strain (for a unit increase in BMI, 49 
= -0.12: 95% CI -0.24, -0.004; P=0.043) (Table 3). No significant interaction was found 50 
©    2015 Macmillan Publishers Limited. All rights reserved.
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between BMI and metabolic health. Peak systolic strain was significantly inversely correlated 51 
with liver fat (ρ = -0.35; p=0.0042) but not with VAT:SAT ratio (ρ = -0.12; P=0.36) .  52 
 53 
In terms of LV diastolic function, left atrial size and E/E‟ ratio were not significantly 54 
different across the groups (Table 2). Early (E‟) and late (A‟) diastolic tissue velocity and 55 
early diastolic strain rate (EDSR) were significantly different between groups (all P<0.01) 56 
with lower levels observed for the metabolically unhealthy.  Linear regression showed that 57 
patients with metabolic syndrome had significantly lower E‟ (-1.89: 95% CI -2.73, -1.06; 58 
P<0.001) and EDSR (-0.28:  95% CI: -0.41, -0.15; P<0.001) with a progressive reduction 59 
occurring in both cardiac parameters as the number of metabolic syndrome components 60 
increased (Figures 2B and 2C, Table 4). Of the metabolic syndrome components, glucose 61 
was significantly associated with early diastolic tissue velocity (for a one SD increase: -0.30: 62 
95% CI -0.54, -0.07; P=0.012)(Table 4) and systolic BP was significantly associated with 63 
EDSR (for a one SD increase: -0.44: 95% CI -0.76, -0.11; P=0.01)(Table 4).  64 
 65 
As to the feasibility and reproducibility of echocardiography, for tissue velocity, global peak 66 
systolic strain (%) and strain rate (s
-1
), the intra-observer and inter-observer variability was 67 
0.3 ± 0.3, 1.3 ± 0.5 %, 0.1 ± 0.1 s
-1 
and 0.4 ± 0.3, 1.2 ± 0.8 % and 0.3 ± 0.2 s
-1 
respectively.
 
 68 
Despite care taken during image acquisition, it was not possible to analyse 8% of left 69 
ventricular segments due to artefact and signal noise.  70 
 71 
Discussion 72 
This integration of detailed MRI and MRS analysis of body composition, echocardiographic 73 
assessment of myocardial function and evaluation of metabolic health has provided an 74 
opportunity to compare the determinants of myocardial function in four distinct phenotypes: 75 
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non-obese, mean age and BMI-matched metabolically healthy and metabolically unhealthy 76 
individuals (non-obese MS- and MS+, respectively) and obese, mean age and BMI-matched 77 
metabolically healthy and metabolically unhealthy individuals (obese MS- and MS+, 78 
respectively). We find that subclinical impairment of myocardial function is more closely 79 
associated with adverse metabolic health than with either obesity or BMI. Echocardiographic 80 
measures of both diastolic and systolic myocardial function were reduced in the 81 
metabolically unhealthy vs healthy groups, irrespective of obesity. We also find that 82 
metabolic health is more closely associated with increased liver fat than visceral fat 83 
deposition suggesting fat distribution is pivotal. These observational data help provide 84 
mechanistic insight into the pathophysiology of (obesity-related) CVD and potentially 85 
support the epidemiological observations of differential cardiovascular outcomes among 86 
metabolically healthy and unhealthy, lean and obese individuals. 87 
 88 
There is evidence from transgenic animal and human models that the capacity of SAT to 89 
expand with over-feeding determines to what extent excess lipids „spill over‟ into ectopic 90 
sites (e.g. skeletal muscle, liver and cardiac muscle), and therefore whether obesity is 91 
metabolically healthy or unhealthy 
37, 38
. However, there is currently no consensus on how to 92 
define metabolic health or metabolically healthy obesity except for the inclusion of obesity 93 
(BMI>30 kg/m
2
) as a criterion. Some studies use the number of components of the MS, 94 
although with different diagnostic criteria 
39
. Others have used measures of insulin resistance, 95 
with inconsistencies in definitions or diagnostic criteria (use of HOMA-IR, Matsuda index 96 
derived from an oral glucose tolerance test or from the glucose disposal rate). Several studies 97 
have used measures of inflammation including C-reactive protein measurements. Large 98 
variations in reported prevalence of MHO (i.e. our obese MS- group) are a function of the 99 
varied criteria used to define this phenotype 
39
. Examining the impact of metabolic health on 100 
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myocardial function, Seo et al and Wong et al have demonstrated subclinical left ventricular 101 
dysfunction in patients with an increased metabolic burden compared to control groups 
22, 23
. 102 
However these studies provide no data on different body composition phenotypes.  103 
 104 
Our findings are consistent with several large-scale epidemiological studies suggesting that 105 
metabolically healthy (obese and non-obese) individuals have a lower risk of CVD than 106 
metabolically unhealthy (obese and non-obese) individuals 
12, 13, 15
 although this is not 107 
universally agreed 
18, 19
. Morkedal et al. have demonstrated disparate effects on coronary 108 
heart disease and heart failure, which may account for the contrasting conclusions 
17, 40
. 109 
 110 
There are several potential mechanisms whereby metabolically unhealthy individuals may 111 
have impaired myocardial performance. The metabolically unhealthy group tended to have 112 
higher IHCL.  Previous studies demonstrated that NAFLD is associated with increased levels 113 
of both intra-pericardial and extra-pericardial fat, which may adversely influence cardiac 114 
metabolism 
41-43
.  Thus metabolically unhealthy patients may also have increased liver and 115 
intra-myocardial triglyceride, leading to lipotoxicity and apoptosis of cardiac myocytes, 116 
potentially contributing to myocardial dysfunction 
44
.  However, in our study the difference in 117 
liver triglyceride did not reach statistical significance and we did not measure cardiac 118 
triglyceride. Metabolically unhealthy individuals have increased levels of inflammatory 119 
markers (interleukins, tumour necrosis factor-alpha and high sensitivity CRP), which can 120 
result in cardiac fibrosis and myocardial stiffening 
45, 46
 and increased circulating levels of the 121 
liver-secreted glycoprotein fetuin A which further induces subclinical inflammation and 122 
perturbs lipid and glucose metabolism 
6, 47
. Hyperinsulinaemia and/or insulin resistance may 123 
also be implicated through abnormal LV energy metabolism 
41
; indeed the cardiovascular 124 
benefit derived from bariatric surgery was strongly associated with reduced fasting insulin 125 
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concentration 
48
. It has been suggested the protective effect of MHO on outcomes may be due 126 
to higher levels of cardiorespiratory fitness but we found no evidence to support this 
49
.  127 
 128 
These findings may have therapeutic implications. Diastolic myocardial abnormalities are 129 
associated with an increased risk of cardiovascular events and cardiac and all-cause mortality 130 
50, 51
. Early detection of myocardial dysfunction may provide an opportunity for patients to 131 
modify their lifestyles, thereby affording the opportunity for primary prevention and reducing 132 
mortality risk. In the SOS (Swedish Obese Subjects) trial, a prospective, controlled, long-133 
term study of bariatric surgery in morbidly obese people, weight loss significantly improved 134 
cardiovascular outcomes 
48
. Obesity is of course associated with a variety of other medical 135 
complications besides T2DM and CVD, not related to metabolic health but caused by the 136 
mechanical consequences of obesity e.g. obstructive sleep apnoea or lower limb osteoarthritis 137 
or by so far unknown mechanisms e.g. the association with certain types of cancer. 138 
Furthermore, there are significant functional and psychological sequelae of obesity, which are 139 
again unrelated to metabolic health. However these findings would indicate that preventative 140 
strategies in obesity must be driven by disease-specific end-points (metabolic, mechanical 141 
and functional end points) rather than simply driven quantitatively by weight loss.   142 
The study has several limitations. Due to the small group sizes for the metabolic analysis, it 143 
was not possible to calculate robust estimates. Furthermore, the small sample size also led to 144 
large variability within the measurements. However the sample size is large enough to 145 
observe clinically and statistically significant differences between the groups. It must be 146 
noted that our cohort sampling strategy may have led to a bias in the metabolically unhealthy 147 
cohort toward an abnormal phenotype that is predisposed to myocardial functional 148 
abnormalities as these patients required specialist care.  Likewise, recruitment of "healthy 149 
participants" from the community may have exaggerated the bias away from the null with 150 
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"healthy volunteer" bias.  A further limitation is the possibility that a proportion of our 151 
participants may have undiagnosed atherosclerotic disease, contributing to the apparent 152 
myocardial abnormalities. However, it was not feasible to undertake coronary angiography or 153 
myocardial functional imaging in our participants to completely exclude silent coronary 154 
artery disease but all patients were screened with clinical assessment, echocardiography and 155 
exercise electrocardiography for evidence of coronary artery disease.  We were also unable to 156 
measure serum fetuin A concentrations or markers of inflammation due to sample volume 157 
limitations.  158 
 159 
Conclusion The metabolic sequelae associated with unhealthy obesity appear to underlie the 160 
functional abnormalities in myocardial systolic and diastolic function, so metabolically 161 
healthy obese subjects have normal myocardial performance. This finding may help explain 162 
the epidemiological associations of metabolically healthy obesity with lower cardiovascular 163 
morbidity and mortality.  164 
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Figure 1 Influence of body mass index and metabolic syndrome on indices of myocardial 
function (A Peak systolic strain, PSS; B Early diastolic tissue velocity, E‟; C Early diastolic 
strain rate, EDSR).  
 
Figure 2 Progressive effect of the number of components of metabolic syndrome on indices 
of myocardial function (A, peak systolic strain, PSS; B E‟ early diastolic tissue velocity; C, 
early diastolic strain rate).   
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Table 1 Clinical, biochemical, metabolic, and body composition characteristics of study participants.  
 Non-obese, MS- 
(n=28) 
Non-obese, MS+ 
(n=10) 
Obese, MS - 
(n=15) 
Obese, MS+ 
(n=12) 
P value 
Age (years) 50.0 ± 7.4 53.2 ± 13.2 45.7 ± 10.3 52.9 ± 5.9 0.127 
Male gender (no. %) 14 (50%) 5 (50%) 6 (40%) 6 (50%) 0.939 
Body mass index (kg m
-2
) 25.9 ± 2.3 26.8 ± 2.0 35.3 ± 4.1 33.6 ± 3.8 <0.001 
Fat free mass (kg) 52.8 (40.9-67.0) 55.8 (41.1-63.0) 54.3 (51.9-66.6) 62.0 (47.2-67.5) 0.957 
Waist circumference (cm) 92.9 ± 8.2 98.8 ± 5.3 115.7 ± 10.9 108.3 ± 9.9 < 0.001 
Systolic blood pressure (mmHg) * 121 (118-132) 118 (119-143) 125 (119-130) 135 (123-144) 0.515 
10 year risk of CV event (%)* 2.5 (1.0-4.9) 5.1 (2.7-8.8) 1.8 (1.4-3.4) 6.6 (3.5-9.1) 0.038 
V02 max * (ml/fat free mass/min) 43.9 (40.7-49.4) 38.4 (32.5-42.5) 43.6 (40.3-45.9) 42.7 (36.2-45.7) 0.475 
Current smoker (no. %) 3 (12%) 2 (20%) 1 (7%) 2 (17%) 0.724 
History of hypertension (no. %) 3 (11%) 1 (10%) 0 6 (50%) 0.004 
Total cholesterol (mmol/L) 5.7 ± 1.1 6.8 ± 2.3 5.1 ± 1.1 6.1 ± 2.3 0.098 
HDL cholesterol (mmol/L) 1.8 ± 0.6 1.4 ± 0.5 1.3 ± 0.3 1.2 ± 0.3 0.001 
LDL cholesterol (mmol/L) 3.2 ± 1.5 3.7 ± 3.0 3.2 ± 0.9 2.9 ± 2.9 0.820 
Triglycerides (mmol/L) 1.4 ± 0.9 2.9 ± 1.7 1.5 ± 0.7 4.6 ± 5.2 0.001 
Glucose (mmol/L) 4.7 ± 0.4 5.3 ± 0.5 4.9 ± 0.5 5.5 ± 0.7 < 0.001 
Gamma-glutamyl transpeptidase *  27 (16-48) 35 (27-81) 27 (19-46) 79 (37-98) 0.062 
Aspartate aminotransferase * 24 (20-27) 24 (19-33) 18 (16-24) 25 (19-43) 0.521 
Alanine aminotransferase *  24 (18-39) 28 (19-45) 20 (16-34) 40 (18-73) 0.322 
Insulin (pmol/l) * 75.1 (58-96) 84.4 (54-111) 107.7 (91-130) 122.6 (103-139) 0.002 
Adiponectin (ng/ml) * 8027 (6300-16240) 11869 (7246-4417) 7416 (6095-8600) 6344 (5044-1085) 0.300 
Abdominal sub-cutaneous fat (SAT) (L) 6.1 ± 2.7 6.7 ± 1.3 12.9 ± 5.3 10.0 ± 3.2 < 0.001 
Abdominal visceral fat (VAT) (L) 3.6 ± 1.7 4.9 ± 1.5 5.8 ± 1.9 5.5 ± 2.3 0.001 
VAT:SAT * 0.6 (0.4-0.8) 0.7 (0.5-1.1) 0.4 (0.4-0.6) 0.6 (0.3-1.0) 0.2845 
Hepatic triglyceride level (%) * 2.0 (1.1-12.8) 12.4 (1.6-33.2) 3.3 (2.4-7.7) 11.8 (6.1-18.0) 0.055 
Values quoted are mean ± standard deviation or as median with interquartile range (*). P-values have been corrected for multiple 
comparisons using Sime’s procedure and declared as significant if a p<0.017 was achieved. 
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Table 2 Echocardiographic (M-mode, Doppler and tissue Doppler) characteristics of study participants.  
 
 
Non-obese, MS- 
(n=28) 
Non-obese, MS+ 
(n=10) 
Obese, MS- 
(n=15) 
Obese, MS+ 
(n=12) 
 
P value 
LV mass (g) 137 ± 40 131 ± 29 166 ± 35 162 ± 18 0.029 
LV mass index (g/m
2
) 72 ± 15 70 ± 16 74 ± 14 77 ± 9 0.675 
LV septal wall thickness (cm) 1.0 ± 0.2 1.1 ± 0.2 1.0 ± 0.2 1.1 ± 0.1 0.427 
LV posterior wall thickness (cm) 1.0 ± 0.1 0.9 ± 0.2 1.0 ± 0.1 1.1 ± 0.2 0.047 
LV internal diameter (cm) 4.1 ± 0.5 4.2 ± 0.6 4.7 ± 0.5 4.3 ± 0.5 0.061 
LVEF (%) 65 ± 7 61 ± 9 62 ± 7 64 ± 7 0.577 
LA area (cm
2
) 16 ± 4 14 ± 3 17 ± 3 17 ± 3 0.282 
E (m/s) 0.68 ± 0.16 0.57 ± 0.10 0.67 ± 0.14 0.60 ± 0.14 0.141 
A (m/s) 0.71 ± 0.14 0.74 ± 0.25 0.67 ± 0.15 0.76 ± 0.14 0.454 
E/A ratio 1.1 ± 0.3 0.9 ± 0.2 1.2 ± 0.3 1.0 ± 0.3 0.021 
E/E’ ratio 11.4 ± 2.5 12.4 ± 2.5 10.1 ± 2.0 12.0 ± 2.3  0.079 
IVRT (ms) 69 ± 20 72 ± 33 61 ± 28 61 ± 27 0.129 
Peak global S’ (cm/s) 6.1 ± 1.3 5.3 ± 0.9 5.5 ± 1.0 5.2 ± 0.7 0.040 
Peak global E’ (cm/s) 7.2 ± 1.7 4.7 ± 0.9 7.23 ± 1.5 5.9 ± 1.6 < 0.001 
Peak global A’ (cm/s) 6.2 ± 1.6 7.4 ± 1.6 5.6 ± 1.6 7.0 ± 1.1 0.015 
Peak systolic longitudinal strain (%) 19.6 ± 2.6 17.1 ± 2.2 18.9 ± 2.1 16.4 ± 2.4 0.001 
Peak systolic longitudinal strain rate (s
-1
) 1.2 ± 0.3 1.3 ± 0.2 1.4 ± 0.4 1.1 ± 0.2 0.255 
Peak early diastolic longitudinal strain rate (s
-1
) 1.7 ± 0.3 1.4 ± 0.2 1.6 ± 0.3 1.4 ± 0.1 0.001 
Peak late diastolic longitudinal strain rate (s
-1
) 1.5 ± 0.4 1.6 ± 0.3 1.5 ± 0.6 1.4 ± 0.3 0.780 
LV left ventricular, LVEF left ventricular ejection fraction, LA left atrial, IVRT iso-volumetric relaxation time 
Values quoted are mean ± standard deviation. P-values have been corrected for multiple comparisons using Sime’s procedure and declared as 
significant if a P<0.017 was achieved.
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Table 3 Regression analyses for peak systolic strain, early diastolic tissue velocity and early diastolic strain rate according to presence or 
absence of metabolic syndrome. The results show both the unadjusted estimates and those adjusted for age and gender. 
 
  Peak Systolic Strain  Early Diastolic Tissue Velocity  Early Diastolic Strain Rate 
  Estimate CI P-value  Estimate CI P-value  Estimate CI P-value 
 
Unadjusted 
 Metabolic Syndrome 
 BMI 
 
  
 
-2.45 
-0.12 
 
 
(-3.67, -1.23) 
(-0.24, -0.01) 
 
 
<0.001 
0.031 
  
 
-1.89 
0.02 
 
 
(-2.73, -1.06) 
(-0.06, 0.10) 
 
 
<0.001 
0.597 
  
 
-0.28 
-0.001 
 
 
(-0.41, -0.15) 
(-0.01, 0.01) 
 
 
<0.001 
0.822 
Adjusted 
 Metabolic Syndrome 
 BMI 
 Age 
 Gender 
  
-2.45 
-0.12 
0.003 
-0.46 
 
(-3.74, -1.15) 
(-0.24, -0.004) 
(-0.07, 0.08) 
(-1.68, 0.77) 
 
<0.001 
0.043 
0.915 
0.458 
  
-1.61 
-0.01 
-0.06 
0.37 
 
(-2.43, -0.78) 
(-0.08, 0.70) 
(-0.10, -0.01) 
(-0.41, 1.15) 
 
<0.001 
0.863 
0.013 
0.341 
  
-0.26 
-0.002 
-0.003 
0.04 
 
(-0.40, -0.13) 
(-0.02, 0.01) 
(-0.01, 0.003) 
(-0.09, 0.17) 
 
<0.001 
0.637 
0.331 
0.522 
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Table 4 A Univariate analyses for peak systolic strain, early diastolic tissue velocity and early diastolic strain rate according to number of 
metabolic syndrome (MS) components. Results are presented as the mean difference in cardiac function reference to zero components and 
corresponding 95% confidence interval (CI). B Multivariable linear regression analysis for peak systolic strain, early diastolic tissue velocity 
and early diastolic strain rate, adjusted for age and gender.  All variables have been standardised and results are expressed as the SD change in 
cardiac function associated to a one SD increment in independent variable. 
 
A 
  Peak Systolic Strain  Early Diastolic Tissue Velocity  Early Diastolic Strain Rate 
  Estimate CI P  Estimate CI P  Estimate CI P 
 
MS components 
1 
2 
3 
4 
5 
  
 
-0.50 
-2.39 
-3.53 
-4.15 
-7.87 
 
 
(-2.63, 1.62) 
(-4.47, -0.31) 
(-5.71, -1.35) 
(-6.63, -1.66) 
(-12.69, -3.04) 
 
 
0.637 
0.025 
0.002 
0.001 
0.002 
  
 
-0.52 
-0.64 
-2.30 
-2.25 
-4.08 
 
 
(-2.04, 1.00) 
(-2.13, 0.85) 
(-3.87, -0.75) 
(-4.03, -0.47) 
(-7.54, -0.62) 
 
 
0.499 
0.392 
0.004 
0.014 
0.021 
  
 
-0.04 
-0.14 
-0.37 
-0.34 
-0.42 
 
 
(-0.27, 0.19) 
(-0.37, 0.08) 
(-0.61, -0.13) 
(-0.61, -0.07) 
(-0.95, 0.11) 
 
 
0.741 
0.214 
0.003 
0.015 
0.117 
 
B 
  Peak Systolic Strain  Early Diastolic Tissue Velocity  Early Diastolic Strain Rate 
  Estimate CI P-value  Estimate CI P-value  Estimate CI P-value 
Waist Circumference 
Systolic BP 
Diastolic BP 
HDL Cholesterol 
Triglycerides 
Glucose 
Age 
Gender 
 -0.07 
-0.10 
-0.19 
0.31 
-0.29 
-0.09 
-0.04 
0.35 
(-0.34, 0.20) 
(-0.40, 0.21) 
(-0.50, 0.12) 
(-0.00, 0.63) 
(-0.53, 0.04) 
(-0.34, 0.16) 
(-0.30, 0.22) 
(-0.17, 0.86) 
0.615 
0.535 
0.232 
0.050 
0.021 
0.463 
0.768 
0.183 
 0.09 
-0.24 
-0.10 
0.23 
0.01 
-0.30 
-0.28 
0.42 
(-0.16, 0.35) 
(-0.53, 0.06) 
(-0.39, 0.20) 
(-0.07, 0.53) 
(-0.22, 0.24) 
(-0.54, -0.07) 
(-0.53, -0.03) 
(-0.07, 0.91) 
0.469 
0.110 
0.523 
0.129 
0.897 
0.012 
0.030 
0.090 
 0.01 
-0.44 
0.16 
0.21 
-0.17 
-0.02 
-0.15 
0.36 
(-0.27, 0.30) 
(-0.76, -0.11) 
(-0.18, 0.49) 
(-0.12, 0.55) 
(-0.43, 0.09) 
(-0.28, 0.24) 
(-0.43, 0.14) 
(-0.19, 0.91) 
0.921 
0.010 
0.345 
0.209 
0.187 
0.882 
0.302 
0.199 
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